In our study, it was shown that the low-risk patients had significantly higher levels of PD-1, PD-L1, PD-L2, CD80, CD86, and CTLA-4 than the high-risk patients, suggesting this low-risk subpopulation of breast cancer patients might benefit more from immune checkpoint blockade therapy. Here, CD80 is linked to breast carcinoma.